SG153647A1 - Antineoplastic combinations - Google Patents

Antineoplastic combinations

Info

Publication number
SG153647A1
SG153647A1 SG200507698-9A SG2005076989A SG153647A1 SG 153647 A1 SG153647 A1 SG 153647A1 SG 2005076989 A SG2005076989 A SG 2005076989A SG 153647 A1 SG153647 A1 SG 153647A1
Authority
SG
Singapore
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
antinoeplastic
neoplasms
Prior art date
Application number
SG200507698-9A
Other languages
English (en)
Inventor
Gary Dukart
Joseph Gibbons James Jr
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG153647A1 publication Critical patent/SG153647A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200507698-9A 2001-06-01 2002-05-29 Antineoplastic combinations SG153647A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29519001P 2001-06-01 2001-06-01
US29523601P 2001-06-01 2001-06-01

Publications (1)

Publication Number Publication Date
SG153647A1 true SG153647A1 (en) 2009-07-29

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200507698-9A SG153647A1 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Country Status (17)

Country Link
EP (1) EP1392286A2 (no)
JP (1) JP2004532883A (no)
KR (1) KR100875611B1 (no)
CN (1) CN100496485C (no)
AU (2) AU2002259309B2 (no)
BR (1) BR0210101A (no)
CA (1) CA2447732A1 (no)
CO (1) CO5540294A2 (no)
EA (1) EA007530B1 (no)
HU (1) HUP0400006A2 (no)
IL (1) IL158800A0 (no)
MX (1) MXPA03010907A (no)
NO (1) NO20035317L (no)
NZ (1) NZ529877A (no)
PL (1) PL367267A1 (no)
SG (1) SG153647A1 (no)
WO (1) WO2002098416A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269603B1 (en) * 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NO20220050A1 (no) * 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
EP2591775A1 (en) * 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
HUE039643T2 (hu) * 2007-03-07 2019-01-28 Abraxis Bioscience Llc Rapamicin rákellenes szert és albumint tartalmazó nanorészecske
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20180128078A (ko) 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DE69209183T2 (de) * 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP2269603B1 (en) * 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEOERGER B ET AL: "ANTITUMOR ACTIVITY OF THE RAPAMYCIN ANALOG CCI-779 IN HUMAN PRIMITIVE NEUROECTODERMAL TUMOR/MEDULLOBLASTOMA MODELS AS SINGLE AGENT AND IN COMBINATION CHEMOTHERAPY" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 4, no. 61, 15 February 2001 (2001-02-15), pages 1527-1532 *
SHI Y ET AL: "Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro." CANCER RESEARCH, (1995 MAY 1) 55 (9) 1982-8. , vol. 55, no. 9, - 1995 pages 1982-8 *

Also Published As

Publication number Publication date
IL158800A0 (en) 2004-05-12
WO2002098416A3 (en) 2003-03-13
EP1392286A2 (en) 2004-03-03
HUP0400006A2 (hu) 2004-04-28
JP2004532883A (ja) 2004-10-28
NO20035317L (no) 2003-12-22
CN1646120A (zh) 2005-07-27
AU2008202690A1 (en) 2008-07-10
WO2002098416A2 (en) 2002-12-12
EA200301319A1 (ru) 2004-04-29
CA2447732A1 (en) 2002-12-12
PL367267A1 (en) 2005-02-21
NZ529877A (en) 2006-08-31
KR20040025923A (ko) 2004-03-26
AU2002259309B2 (en) 2008-05-01
BR0210101A (pt) 2004-06-08
CO5540294A2 (es) 2005-07-29
MXPA03010907A (es) 2004-02-17
EA007530B1 (ru) 2006-10-27
KR100875611B1 (ko) 2008-12-24
NO20035317D0 (no) 2003-11-28
CN100496485C (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
SG170612A1 (en) Antineoplastic combinations
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
SG152906A1 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
ECSP056001A (es) Combinaciones antineoplásicas
SG153647A1 (en) Antineoplastic combinations
TW200503753A (en) Antineoplastic combinations
SG150559A1 (en) Antineoplastic combinations of cci-779 and rituximab
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
ECSP034866A (es) Combinaciones antineoplásticas
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
AR033012A1 (es) Combinaciones antineoplasicas
EP1511753A4 (en) ANTIMICROBIAL MEDIUM AND ITS USE
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
GB0108485D0 (en) Combination therapy
AU2002234165A1 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002083151A3 (en) Compositions and methods for treating an arthritic condition
IL151871A0 (en) Restenosis treatment
IL147696A0 (en) Combination therapy
EP1557169A4 (en) THERAPEUTIC AND / OR PROPHYLACTIC AGENT FOR DYSCHEZIA
AU2002364385A8 (en) Implantable device and the use thereof
MXPA05003282A (es) Forma de dosis de liberacion inmediata que comprende coraza que tiene aberturas en la misma.
GB0112689D0 (en) Dispenser and treatment means
AU2002321974A1 (en) Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents